Skip to content

Novel circrNAs as a biomarker in serum of patients with diabetic cardiomyopathy

Novel circrNAs as a biomarker in serum of patients with diabetic cardiomyopathy

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078846
Enrollment
Unknown
Registered
2023-12-19
Start date
2022-07-13
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic cardiomyopathy

Interventions

control group, NC:none
Diabetes group, DC:none
Diabetic cardiomyopathy group, DCM:none

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 20-70 years old, gender unlimited; (2) 20 kg/m2= BMI =35 kg/m2; (3) The patient voluntarily participated in the experiment and signed the informed consent; (4) Able to communicate well with patients and follow the requirements of the whole experiment; (5) Normal control group: 75g glucose tolerance test was normal; (6) Diabetes group: patients diagnosed with T2DM according to WHO criteria (1999); (7) Diabetic cardiomyopathy group: on the basis of the diagnosis of type 2 diabetes, cardiac ultrasound indicated dilatation of the heart with impaired systolic function, while those without dilatation of the heart had diastolic dysfunction;

Exclusion criteria

Exclusion criteria: (1) Heart failure due to hypertensive heart disease, coronary heart disease, rheumatic valvular heart disease, dilated or hypertrophic cardiomyopathy, atrial fibrillation or other cardiovascular diseases diagnosed or currently diagnosed; (2) Severe diabetic complications, such as proliferative retinopathy, diabetic foot, or diabetic nephropathy (glomerular filtration rate <60ml/min); (3) other significant comorbidities, such as neoplasms, hypothyroidism, hepatorenal insufficiency, immune and rheumatic diseases or major psychiatric disorders; (4) The use of hormones and psychotropic drugs in the past 3 months; (5) Preparing for pregnancy or becoming pregnant; (6) Incomplete examination or incomplete data

Design outcomes

Primary

MeasureTime frame
circular RNA (hsa_circ_0002320 and on);

Countries

China

Contacts

Public ContactLingling Yuan

The Second Hospital of Hebei Medical University

513479342@qq.com+86 189 3113 2205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026